Literature DB >> 1587054

Controversies in determination of epoetin (recombinant human erythropoietin) dosages.

P A Abraham1, W L St Peter, K A Redic-Kill, C E Halstenson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1587054     DOI： 10.2165/00003088-199222060-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  43 in total

Review 1.  Erythropoietin.

Authors:  A J Erslev
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

2.  Experience with daily self-administered subcutaneous erythropoietin.

Authors:  C Granolleras; B Branger; M C Beau; G Deschodt; B Alsabadani; S Shaldon
Journal:  Contrib Nephrol       Date:  1989       Impact factor: 1.580

3.  Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.

Authors:  I C Macdougall; R D Hutton; I Cavill; G A Coles; J D Williams
Journal:  BMJ       Date:  1990-03-10

4.  Self-administered daily subcutaneous recombinant human erythropoietin: an open randomised dose-finding study in ESRD patients receiving peritoneal dialysis.

Authors:  A Slingeneyer; B Faller; B Laroche; B Ehmer; C Mion
Journal:  Contrib Nephrol       Date:  1991       Impact factor: 1.580

5.  Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients.

Authors:  E Sundal; U Kaeser
Journal:  Nephrol Dial Transplant       Date:  1989       Impact factor: 5.992

6.  Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.

Authors:  S F Lui; C B Law; S M Ting; P Li; K N Lai
Journal:  Clin Nephrol       Date:  1991-11       Impact factor: 0.975

7.  Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta.

Authors:  C E Halstenson; M Macres; S A Katz; J R Schnieders; M Watanabe; J T Sobota; P A Abraham
Journal:  Clin Pharmacol Ther       Date:  1991-12       Impact factor: 6.875

8.  Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.

Authors:  J W Eschbach; M H Abdulhadi; J K Browne; B G Delano; M R Downing; J C Egrie; R W Evans; E A Friedman; S E Graber; N R Haley
Journal:  Ann Intern Med       Date:  1989-12-15       Impact factor: 25.391

9.  Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

Authors:  C G Winearls; D O Oliver; M J Pippard; C Reid; M R Downing; P M Cotes
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

10.  Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.

Authors:  S Casati; P Passerini; M R Campise; G Graziani; B Cesana; M Perisic; C Ponticelli
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.